Immediate Impact
2 from Science/Nature 60 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
Works of Frédéric Forget being referenced
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).
2023
Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
2012
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Frédéric Forget | 241 | 162 | 104 | 35 | 489 | |
| Macdonald Js | 247 | 119 | 80 | 20 | 434 | |
| Christoph Heining | 237 | 126 | 231 | 28 | 546 | |
| Tahir Latif | 209 | 108 | 207 | 36 | 569 | |
| K C Lakshmaiah | 305 | 177 | 104 | 27 | 524 | |
| Leopold Öhler | 198 | 103 | 100 | 49 | 469 | |
| Saifee Mullamitha | 220 | 73 | 133 | 31 | 452 | |
| Olugbenga Olowokure | 261 | 154 | 158 | 34 | 494 | |
| Vivek A. Bhadri | 186 | 156 | 172 | 33 | 550 | |
| Fengmei Wang | 116 | 94 | 85 | 33 | 560 | |
| Yoojoo Lim | 188 | 109 | 155 | 55 | 456 |
All Works
Loading papers...